FDC Limited Faces Class II Recall for Defective Timolol Maleate Ophthalmic Solution in US Market
FDC Limited's voluntary Class II recall of 362,544 bottles of Timolol Maleate Ophthalmic Solution due to defective containers signals critical manufacturing control deficiencies. This event impacts US supply chains, particularly distributor Rising Pharma Holdings, Inc., and necessitates immediate procurement risk assessment for ophthalmic drug portfolios. Businesses must evaluate supplier quality systems to mitigate disruption and ensure patient safety.
FDA Enforcement Action: Defective Container Issue Leading to Recall of Timolol Maleate
FDC Limited, an Indian pharmaceutical manufacturer, has initiated a voluntary Class II recall (D-0632-2024) of 362,544 bottles of its Timolol Maleate Ophthalmic Solution USP, 0.5%, Sterile, 5mL. This significant regulatory action stems from a critical quality defect: the presence of a 'yellow colored spike from cap lodged in the nozzle' of the container. This physical defect directly compromises the sterility and integrity of the ophthalmic solution, posing a potential risk of eye irritation, injury, or infection to patients. The recall, initiated on July 18, 2024, affects specific lot numbers 083J022 (Expiration Date: September-25), 083L046 (Expiration Date: November-25), and 083H009 (Expiration Date: July-25). For procurement directors and regulatory affairs heads, this event underscores the imperative of stringent quality control throughout the manufacturing and packaging process. A Class II classification indicates that the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This necessitates an immediate assessment of inventory and supply chain resilience for similar ophthalmic products, particularly those originating from facilities with comparable quality management systems.
Manufacturing Facility Profile: FDC Limited's Waluj, Aurangabad Operations
The recalled Timolol Maleate Ophthalmic Solution was manufactured by FDC Limited at its facility located in B-8 MIDC Industrial Area, Waluj District, Aurangabad, Maharashtra, India. This facility serves as a key supplier for the US market, with products distributed nationwide by Rising Pharma Holdings, Inc. The manufacturing site's role in producing sterile ophthalmic solutions demands adherence to the highest standards of Current Good Manufacturing Practice (cGMP), particularly concerning container closure systems and aseptic processing. The identification of a physical defect like a 'yellow colored spike' suggests potential breakdowns in automated or manual inspection processes, packaging material quality control, or assembly line integrity. For supply chain VPs, this incident highlights the critical need for robust supplier audits that extend beyond documentation review to on-site verification of manufacturing processes, equipment maintenance, and quality assurance protocols at overseas facilities. Reliance on a single manufacturing site without comprehensive oversight can expose businesses to significant disruption when quality issues lead to widespread recalls, impacting product availability and patient trust in the US market.
Supply Chain Exposure: Impact on US Distribution and Procurement for Timolol Maleate
The recall of 362,544 bottles of Timolol Maleate Ophthalmic Solution represents a substantial disruption to the US supply chain for this critical glaucoma medication. Rising Pharma Holdings, Inc., based in New Jersey, is identified as the distributor for these affected lots, indicating their direct exposure to this quality event. Procurement directors must immediately assess their inventory levels and existing contracts for Timolol Maleate, specifically identifying any stock originating from FDC Limited's Aurangabad facility. The nationwide distribution pattern means that pharmacies and healthcare providers across the US will be impacted, requiring rapid communication and product retrieval. This situation creates an urgent need to identify and qualify alternative sources to prevent stockouts and ensure continuity of patient care. Business development executives should recognize that such recalls can erode market share and brand reputation, not only for the manufacturer but also for distributors. Proactive measures, including diversifying supplier bases and implementing real-time quality monitoring, are essential to mitigate the commercial and reputational fallout from such large-scale product withdrawals.
Alternative Sourcing Strategies for Ophthalmic Beta-Blockers like Timolol Maleate
Given the recall of FDC Limited's Timolol Maleate Ophthalmic Solution, procurement teams must prioritize identifying and qualifying alternative suppliers to secure a stable supply of this essential medication. While specific alternative suppliers are not detailed in the current intelligence, Timolol Maleate is a generic drug, suggesting multiple manufacturers globally. Strategic procurement should focus on suppliers with a proven track record of FDA compliance and robust quality systems, particularly for sterile ophthalmic products. Diversifying the supplier base across different geographical regions, beyond traditional hubs like India, can significantly reduce single-point-of-failure risks. Qualification timelines for new suppliers, especially for sterile products, can be lengthy, often spanning 12-24 months due to regulatory requirements, site audits, and stability testing. Therefore, initiating this process immediately is critical. Regulatory affairs heads should prepare for the necessary documentation and validation required to onboard new suppliers, ensuring compliance with FDA regulations for drug product manufacturing and supply chain integrity. This proactive approach minimizes market disruption and safeguards patient access to vital therapies.
Regulatory Compliance History and Escalation Risk for FDC Limited
While the current intelligence does not detail a prior regulatory history for FDC Limited, this Class II recall of Timolol Maleate Ophthalmic Solution constitutes a significant regulatory event that will draw increased scrutiny from the FDA. A defective container issue, particularly one involving a physical contaminant, points to potential deficiencies in the firm's quality management system, manufacturing controls, or packaging processes. Such issues often precede or are indicative of broader cGMP non-compliance that could be identified during future FDA inspections. For regulatory affairs heads, this recall signals an elevated risk of an FDA Form 483 observation or, if unaddressed, a Warning Letter. The FDA's recent focus on manufacturing quality in overseas facilities, as evidenced by parallel events like Essential Wellness Pharma's Class II recall for sterility failures, suggests a low tolerance for quality lapses. Business development executives should understand that a deteriorating regulatory profile can severely impact a company's ability to supply the US market, potentially leading to import alerts or product approval delays. FDC Limited must demonstrate comprehensive corrective and preventive actions (CAPA) to restore confidence and avoid further enforcement actions.
Remediation Requirements and Future Regulatory Scrutiny for FDC Limited
FDC Limited is now obligated to implement a robust remediation plan following this voluntary Class II recall. This plan must address the root cause of the defective container issue, encompassing material quality, manufacturing processes, and quality control checks. Key actions will include a thorough investigation into how the 'yellow colored spike' became lodged in the nozzle, implementing corrective actions to prevent recurrence, and verifying the effectiveness of these changes. For regulatory affairs and quality assurance teams, this means a comprehensive review of their cGMP adherence, particularly in areas of packaging material inspection, line clearance, and finished product inspection. The FDA will closely monitor FDC Limited's response, and a follow-up inspection is highly probable. Failure to adequately address the identified deficiencies could escalate the regulatory consequences, potentially leading to an FDA Warning Letter, an Import Alert on products from the Waluj facility, or even a consent decree. Procurement directors should factor this potential for future regulatory action into their risk assessments, as an Import Alert would effectively halt all shipments from the facility to the US, causing severe supply disruptions for any products sourced from FDC Limited.